Corticotropin-releasing factor (CRF) and norepinephrine (NE) levels are altered in post-traumatic stress disorder and may be related to symptoms of hyperarousal, including exaggerated startle, in these patients. In animals, activation of both systems modulates anxiety behaviours including startle plasticity ; however, it is unknown if they exert their actions orthogonally or dependently. We tested the hypothesis that NE receptor activation is required for CRF effects on startle and that CRF 1 receptor activation is required for NE effects on startle. The study examined the effects of : (1) a 2 agonist clonidine (0.18 mg/kg i.p.), a 1 antagonist prazosin (0.8 mg/kg), and b 1/2 antagonist propranolol (0.8, 8.0 mg/kg) pretreatment on ovine-CRF (oCRF)-(0.6 nmol) induced increases in startle reactivity and disruption of prepulse inhibition (PPI) ; (2) a 2 antagonist atipamezole (1-30 mg/kg) and a 1 agonist cirazoline (0.025-1.0 mg/kg) treatment on startle ; (3) CRF 1 antagonist (antalarmin, 14 mg/kg) pretreatment on atipamezole-(10.0 mg/kg) induced increases in startle. oCRF robustly increased startle and reduced PPI. Pretreatment with clonidine or prazosin, but not propranolol, blocked oCRF-induced increases in startle but had no effect on oCRFinduced disruptions in PPI. Atipamezole treatment increased startle, which was partially attenuated by CRF 1 antagonist pretreatment. Cirazoline treatment did not increase startle. These findings suggest that CRF modulation of startle, but not PPI, requires activation of a 1 adrenergic receptors, while CRF 1 activation also contributes to NE modulation of startle. These data support a bi-directional model of CRF-NE modulation of stress responses and suggest that both systems must be activated to induce stress effects on startle reactivity.
Introduction
The acoustic startle reflex is a defensive behaviour characterized by reflexive contraction of the skeletal musculature in response to sudden intense acoustic stimuli, and is increased under conditions of threat. Prepulse inhibition (PPI) of the startle reflex refers to suppression of the startle reflex when a startling acoustic stimulus is preceded by a weaker prestimulus. Startle reactivity and inhibition of startle are altered in certain anxiety disorders, including posttraumatic stress disorder (PTSD) (Grillon et al. 1996 (Grillon et al. , 1998 Grillon, 2008 ; Pole et al. 2009 ). In PTSD, neurotransmission of corticotropin-releasing factor (CRF), a neuropeptide released in response to stress, may also be altered (Baker et al. 1999 ; Sautter et al. 2003) . CRF levels in cerebrospinal fluid have been found to be higher in PTSD patients compared to control subjects (Baker et al. 1999 ; Bremner et al. 1997) . Given that CRF modulates the startle response (Grillon, 2008 ; Risbrough & Stein, 2006) , one hypothesis is that increases in CRF neurotransmission may contribute to exaggerated startle behaviours [e.g. increased startle magnitude (reactivity) and reduced startle inhibition] observed in PTSD. Identifying the mechanism through which CRF affects startle could therefore be beneficial in providing a target for developing novel compounds to treat anxiety disorders like PTSD.
CRF acts in the brain at two known G-proteincoupled receptors, CRF 1 and CRF 2 (Hauger et al. 2006) . CRF 1 activation is required for CRF-or stress-induced increases in startle reactivity and decreases in PPI (Risbrough et al. 2003 (Risbrough et al. , 2004 ). However, the central mechanism by which CRF exerts its effect on startle plasticity is unclear. One potential mechanism mediating CRF system regulation of startle and PPI may involve the noradrenergic system. The noradrenergic system, originating primarily in the locus coeruleus (LC), consists of a 2 (presynaptic/post-synaptic), a 1 (post-synaptic), and b (post-synaptic) receptors. The hypothesis that the noradrenergic system may mediate the effects of CRF on startle emerges from observations that CRF terminals synapse with dendrites of noradrenergic neurons in the LC and recent studies have labelled CRF 1 receptors in tyrosine-hydroxylase neurons of the LC (Reyes et al. 2006) . Additionally, CRF administration [intracerebroventricularly (icv) or directly into LC] increases norepinephrine (NE) release in the bed nucleus stria terminalis (BNST) (Curtis et al. 1997 ; Dunn et al. 2004 ; Van Bockstaele et al. 1996) , a critical site for CRF-induced increases in startle . The BNST is also densely innervated with noradrenergic fibres from the LC (Forray et al. 2000 ; Koob, 1999) and requires noradrenergic signalling to control fear behaviours (Fendt et al. 2005) . Additionally, CRF receptor antagonist treatment or null mutation of the CRF gene blocks stress-induced changes in extracellular NE (Isogawa et al. 2000 ; Jeong et al. 2000) , suggesting that CRF modulates NE release. Increases in NE signalling have been shown to increase startle both in PTSD patients and in some rodent models (Carasso et al. 1998 ; Davis, 1980 ; Lahdesmaki et al. 2004 ; Morgan et al. 1995 ; Risbrough & Geyer, 2005) . These findings support the hypothesis that CRF's effects on defensive startle behaviour may require activation of the noradrenergic system.
Given that CRF increases startle, NE increases startle under certain conditions, and CRF increases NE release, we predicted that blocking NE signalling would reverse the effects of CRF on startle behaviours. To test this hypothesis, we examined the effects of a 2 agonist (clonidine) pretreatment on CRF-induced changes in startle. Clonidine decreases NE release by activating inhibitory presynaptic a 2 autoreceptors. Second, we examined the contribution of the excitatory a 1 or b post-synaptic receptors to CRF effects on startle via pretreatment with an a 1 antagonist (prazosin), or a b 1/2 adrenergic antagonist (propranolol). To determine if NE receptor activation effects on startle result from CRF receptor activation, we tested the hypothesis that NE activation is sufficient to mimic CRF effects on startle and PPI via treatment with a selective a 2 antagonist that increases NE release (atipamezole) and an a 1 agonist (cirazoline). Finally, we used a CRF 1 antagonist (antalarmin) to determine whether NE signalling-induced changes in startle also require concomitant CRF 1 receptor activation, suggesting reciprocal permissive roles of these systems in this behaviour.
Methods

Subjects
Male C57BL/6J mice (aged 2-3 months ; Jackson Laboratories, USA) were housed in a temperatureand humidity-controlled room (12-h reversed light/ dark cycle, lights off 08:00 hours) (n=7-12/group per experiment). Food and water were available ad libitum. Mice acclimated to the vivarium for at least 1 wk prior to cannulation surgery. All testing occurred between 10:00 and 18:00 hours and was in accordance with the guidelines of the National Institutes of Health's ' Guide for the Care and Use of Laboratory Animals', as approved by UCSD.
Surgery and histological verification
Surgery and histological verification were as described previously (Vinkers et al. 2007) . A 23-gauge 7-mm unilateral guide cannula was placed above the lateral ventricle (flat skull ; anteroposterior, x0.1 mm ; mediolateral, ¡1.1 mm ; dorsoventral, x1.5 mm below dura). Mice recovered for >5 d before testing. A 30-gauge 8-mm injector was used for drug infusions. After study completion, mice were anaesthetized and cannulae placement was checked via dye infusion (1.5 ml). Nine mice were removed from analysis due to incorrect placement.
Apparatus
Startle and PPI testing were performed in ventilated, dark, sound-attenuating commercial startle chambers (39r38r58 cm, SR-LAB system, San Diego Instruments, USA) as described previously (Risbrough et al. 2003) . A loudspeaker provided continuous broadband 65-dB background noise and all acoustic stimuli. Beginning at stimulus onset, 65 consecutive 1-ms readings were recorded to obtain the average magnitude of the mouse's startle response.
Expt 1 : time-course and dose response of ovine-CRF (oCRF)
Drugs
In order to identify a behaviourally active dose and time-point of the CRF 1 -preferring agonist (oCRF) for use in expt 2, mice (n=9-10/group) were treated with 0, 0.06, 0.2, or 0.6 nmol oCRF (0.28-2.8 mg/5 ml icv) (Bachem, USA). Artificial cerebrospinal fluid (aCSF) was the vehicle. Doses were based on previous studies using the non-selective CRF receptor agonist rat/ human (r/h) CRF which dose-dependently increased startle and disrupted PPI (Risbrough et al. 2003 (Risbrough et al. , 2004 .
Behavioural testing
Mice were placed in the startle apparatus immediately following drug infusion ('time 0 '). Startle testing was repeated hourly for 6 h post-infusion, with mice returned to the home cage for 40 min after each test (session duration 20 min). The startle session began with a 2-min acclimation period, followed by presentation of four 120-dB pulse trials (presented at start of the session to achieve a stable level of startle reactivity for the remainder of the session). These trials were immediately followed by a block of trials in which the prepulse intensity varied (10 startle pulse-alone trials, each at 120 dB, 40-ms duration, and 30 prepulse+ pulse trials). The prepulse+pulse trials were evenly divided among the following trial types (10 each) : a 69, 73, or 77-dB prepulse (20 ms) preceding a 120-dB pulse stimulus (40 ms). The time between the prepulse and pulse onset was 100 ms. This block was immediately followed by another block of trials in which the inter-stimulus interval (ISI) between the prepulse and pulse was varied. During the ISI block, seven startle pulse trials, each at 120 dB, were presented. Additionally, 73-dB prepulses preceded a 120-dB stimulus by 20, 120, 360 ms (four trials of each ISI duration). The average inter-trial interval for all trial types throughout the session was 15 s (range 6-21 s). All trial types within the prepulse intensity and ISI trials were presented in a pseudo-random order. The average startle magnitude over the record window (65 ms) was used for all data analysis.
Data analysis
To assess CRF effects over time, startle magnitude in response to the 120-dB pulses was averaged over each session. A two-way analysis of variance (ANOVA) was used with oCRF treatment (0, 0.06, 0.2, 0.6 nmol) as the between-subject and time post-infusion (0-6 h) as the within-subject factors. %PPI was calculated using the formula : 100x average startle of prepulse+pulse trials average startle in pulse-alone trial r100:
Initially a three-way ANOVA, with oCRF treatment as the between-subject factor and prepulse intensity (69, 73, 77 dB) or ISI (20, 120, 360 ms) and post-infusion time as within-subject factors was conducted. Prepulse intensity did not interact with the other factors and thus was removed from the analysis. Tukey's post-hoc analyses followed significant main or interaction effects.
Expt 2 : the role of a 2 , a 1 , and b 1/2 noradrenergic receptors in CRF-induced alterations in startle plasticity
Drugs
Expt 2a : a 2 agonist (clonidine) effects in oCRF-treated mice. Mice (n=9-11/group) received 0.6 nmol oCRF (2.8 mg/5 ml icv) or aCSF vehicle 2 h before testing. They also received the a 2 agonist clonidine (0.09 mg/kg, 5 ml/kg i.p., Tocris, USA) or saline 30 min before and 60 min after oCRF infusion (0.18 mg/kg total dose). Dose and timing of oCRF was based on expt 1 (0.6 nmol has large effects on startle and PPI 2 h post-infusion ; Fig. 1 ). Two injections of clonidine were given to ensure a lasting effect of clonidine over the 2-h pretest and testing interval (Risbrough et al. 2003 (Risbrough et al. , 2004 .
Expt 2b : a 1 antagonist (prazosin) effects in oCRF-treated mice. Mice (n=8-11/group) received oCRF (0.6 nmol icv) or aCSF 2 h before testing. They received the a 1 antagonist prazosin (0.4 mg/kg, 5 ml/kg i.p., SigmaAldrich, USA) or vehicle (3 % Cremophor in water) 30 min before and 1 h after oCRF infusion for a total dose of 0.8 mg/kg. The prazosin dose was based on pilot studies and previous reports in mice (Okuyama et al. 1999 ).
Expt 2c : b 1/2 antagonist (propranolol) effects in oCRFtreated mice. Mice (n=7-11/group) received oCRF (0.6 nmol icv) or aCSF 2 h before testing. The b 1/2 antagonist propranolol (4 mg/kg, 5 ml/kg i.p., Sigma-Aldrich) or saline was given 30 min before and 1 h after oCRF (8 mg/kg total ; Goldschmidt et al. 1984 ; Schank et al. 2008) . To ensure results were not due to non-selectivity of propranolol for b 1/2 receptors, we also used a 10-fold lower dose of propranolol (0.4 mg/ kg per injection, 0.8 mg/kg total) in a separate cohort (n=9-11/group) (Izquierdo & McGaugh, 1985 ; Saha et al. 1991 ; Zarrindast et al. 2004) . To confirm the antagonist activity of propranolol at b 1/2 receptors during the time-frame of our startle test, we examined the effect of this same dose and pre-injection time on clenbuterol-induced disruptions in locomotor activity in a separate group of mice (n=7-11/group). Timing of propranolol administration before locomotor testing was identical to that in the startle tests, with propranolol (4 mg/kg) administered 2 1 2 h and 1 h before testing. Clenbuterol was administered 30 min before testing. Data were analysed over the first 30 min of the locomotor test to match the duration of the startle session (see below).
Behavioural testing
A 65-dB background was presented continuously during the session which lasted 30 min. The session began with a 5-min acclimation period followed by presentation of five 120-dB pulse trials (average intertrial interval, 15 s) (block 1). These pulses were followed immediately by startle threshold response trials (block 2), variable prepulse intensity trials (block 3), and variable ISI trials (block 4). Five 120-dB pulse trials were presented at the end of the session (block 5) to measure startle habituation to 120-dB pulses across the session (i.e. blocks 1-5). During the threshold response block, 20 startle pulse trials varied in intensity (four each at 80, 90, 100, 110, and 120 dB, 40 ms duration) were presented. Next, the variable prepulse intensity block consisted of 12 startle pulse-alone trials (each at 120 dB) and 30 prepulse+pulse trials. The prepulse+pulse trials were evenly divided among the following trial types (10 each) : 68, 71, or 77 dB prepulse (20 ms) preceding a 120-dB pulse stimulus (40 ms). The time between prepulse and pulse onset was 100 ms. During the variable ISI block, eight startle pulse trials (120 dB) were presented. In addition, 71-dB prepulses preceded a 120-dB stimulus by 25, 50, 100, 200, or 500 ms (four trials each). All trial types were presented in a pseudo-random order.
Data analysis
A two-or three-way ANOVA was used with pretreatment and/or treatment as between-subject factors and pulse intensity (80, 90, 100, 110, 120 dB), prepulse intensity (68, 71, 77 dB), ISI (25, 50, 100, 200, 500 ms) or startle block (blocks 1-5) as within-subject factors. Tukey's post-hoc analyses followed significant main or interaction effects.
Expt 3 : the role of CRF 1 receptors in noradrenergic modulation of startle Drugs Expt 3a : a 2 antagonist (atipamezole) effects on startle. Mice (n=11/dose) were treated with the a 2 antagonist atipamezole (1, 3, 10, 30 mg/kg, 10 ml/kg s.c. ; Pfizer Health, USA) or saline 30 min before testing (doses and timing based on Risbrough & Geyer, 2005) .
Expt 3b : a 1 agonist (cirazoline) effects on startle. Mice (n=11/dose) were treated with the a 1 agonist cirazoline (0.25, 0.5, 1.0 mg/kg, 5 ml/kg i.p.) (Sigma) or saline 5 min before testing (Alsene et al. 2006 ; Barr et al. 2006 ; Carasso et al. 1998 ; Menon et al. 1990 ; Shilling et al. 2004 ; Varty et al. 1999) . Based on expt 3b, mice were treated with lower doses of cirazoline (0.025, 0.083, 0.25 mg/kg, 5 ml/kg i.p.) or saline 5 min before testing (n=10-11/dose). (19 % DMSO in saline) 1 h before testing (Bale & Vale, 2003 ; Djouma et al. 2006) . Atipamezole (10 mg/kg s.c.) or saline was administered 30 min before testing.
Behavioural testing
The startle session used in expts 3a-3c was identical to that used in expts 2a-2c except it did not contain an ISI block.
Data analysis
Data analysis was identical to expt 2.
Results
Expt 1 : time-course and dose response of oCRF
The effect of oCRF on average startle magnitude depended upon post-infusion time (oCRFrtime : F 18,198 =2.81, p<0.0002 ; Fig. 1 a) . Subsequent analysis at each time-point indicated that oCRF significantly increased startle magnitude at 0, 1, 2, and 3 h post-infusion. Post-hoc analysis indicated that at 0, 1 and 2 h post-infusion, 0.2 and 0.6 nmol oCRF significantly increased startle (p<0.05, vs. vehicle). At 1 h, 0.6 nmol also elevated startle compared to 0.06 nmol (p<0.05). At 3 h, 0.6 nmol continued to increase startle (p<0.05, vs. vehicle). oCRF treatment significantly decreased %PPI (oCRF : F 3,33 =4.15, p<0.05) (Fig. 1 b) over the majority of the testing period (oCRFrtime : F 18,198 =1.40, p= 0.13). Inspection of the data suggests that the two highest doses (0.2 and 0.6 nmol) disrupted PPI to the greatest extent at 2 h post-infusion (Fig. 1b) . oCRF (0.6 nmol) similarly decreased %PPI at 120 ms ISI (oCRFrISI : F 6,66 =5.96, p=0.0001 ; p<0.05, 0.6 nmol vs. vehicle, post-hoc test). At the shorter ISI trial (20 ms), oCRF increased %PPI (p<0.05, 0.2 nmol vs. vehicle ; p<0.1, 0.6 nmol vs. vehicle, post-hoc data ; data not shown). These ISI-dependent effects of CRF on PPI are consistent with previous observation in rats (Conti et al. 2009 ) and suggest that CRF effects on PPI may be via alterations in the speed of prepulse processing (i.e. shifting the time window of prepulse effects on startle reactivity ; Graham, 1975) .
Expt 2 : the role of a 2 , a 1 , and b noradrenergic receptors in CRF-induced alterations in startle plasticity Expt 2a : a 2 agonist (clonidine) effects in oCRF-treated mice During the startle threshold test, oCRF increased startle magnitude to high-intensity pulses and this effect was reduced by pretreatment with clonidine, the a 2 agonist (intensityrclonidineroCRF : F 4,140 =4.32, p= 0.005 ; Table 1 ). A follow-up two-way ANOVA at each intensity confirmed a significant clonidineroCRF interaction at 120-dB pulse (F 1,35 =4.53, p<0.05). Post-hoc tests indicated that startle magnitude in the oCRF/ Veh group was significantly higher relative to all other groups (p<0.05).
oCRF-induced increases in startle magnitude were predominantly present in the initial blocks of the session, which was significantly reduced by clonidine pretreatment ( Fig. 2a ; blockroCRF : F 4,140 = 6.07, p<0.05 ; blockrclonidineroCRF : F 4,140 =3.05, p<0.05). Follow-up two-way ANOVA conducted at each block confirmed a significant clonidineroCRF interaction at blocks 1 and 2 (F 1,35 >4.39, p<0.05). Posthoc analyses indicated that startle magnitude in the oCRF/Veh group was significantly higher compared to all other groups during blocks 1 and 2 (p<0.05, oCRF/Veh vs. Veh/Veh, Veh/clonidine, oCRF/clonidine) (Fig. 2 a, right) .
As expected, %PPI increased with prepulse intensity (F 2,70 =97.61, p=0.0001) and decreased with oCRF administration (F 1,35 =17.71, p=0.001). The effect of oCRF on PPI appeared dependent upon intensity and clonidine (intensityrclonidineroCRF : F 2,70 =3.63, p<0.05). However, two-way ANOVAs at each intensity indicated that oCRF effects on PPI were not significantly altered by clonidine pretreatment (Table 1) . A similar pattern of PPI results was found from the ISI test (data not shown).
Expt 2b : a 1 antagonist (prazosin) effects in oCRF-treated mice oCRF-induced increases in startle magnitude were significantly reduced by the a 1 antagonist prazosin at specific startle pulse intensities (Table 1 ; intensityr prazosinroCRF : F 4,140 =3.29, p=0.01). Two-way ANOVAs conducted at each intensity revealed a significant interaction at the 80-dB and 120-dB pulses (prazosinroCRF : F 1,38 >4.10, p<0.05). At these intensities, the startle magnitude in oCRF/Veh was significantly higher relative to all other groups (p<0.05, oCRF/Veh vs. Veh/Veh, Veh/prazosin, oCRF/prazosin).
oCRF-induced increases in startle were again greatest in the initial blocks (Fig. 2 b ; blockroCRF : F 4,140 =3.44, p=0.01). There was also an overall significant interaction between oCRF and prazosin on startle reactivity (oCRFrprazosin : F 1,35 =4.33, p<0.05) (Fig. 2 b, right) . Post-hoc analyses indicated that startle magnitude in oCRF/Veh was significantly greater than all other groups during blocks 1 and 2 (p<0.05). During block 5, startle magnitude remained significantly greater in the oCRF/Veh group compared to Veh/Veh and Veh/prazosin (p<0.05) and there was a trend towards a significant difference compared to oCRF/prazosin (p<0.1). oCRF-induced disruption of PPI was not affected by prazosin (Table 1) .
The effect of oCRF on startle magnitude was greatest at the 90-dB and 120-dB pulses (intensityroCRF : F 4,128 =6.98, p=0.0000, p<0.05 post-hoc test vs. Veh/ Veh) ( Table 1 ). As we have seen throughout, oCRF increases in startle magnitude were highest during the initial blocks (blockroCRF : F 4,128 =6.65, p<0.0001, Fig. 2 c) . A significant main effect of oCRF was observed during block 1 (oCRF : F 1,32 =15.57, p<0.0004) (Fig. 2 c) . Although the main effects of oCRF were maintained during blocks 2-5 (F 1,32 >8.13, p<0.008), oCRF-induced startle increases were not reversed by propranolol (b 1/2 antagonist) in any block (Fig. 2 c,  right) . oCRF-induced disruptions in PPI (intensityr oCRF : F 2,64 =8.28, p<0.005 ; at 68 dB and 71 dB, main effects of oCRF were significant : F 1,32 >4.79, p<0.05), were unaffected by propranolol (Table 1) . In a similar experiment using a lower dose of propranolol (0.8 mg/ kg total) we again found that oCRF-induced increases in startle reactivity and decreases in PPI were not reversed by propranolol (data not shown).
Conversely, this same dose and timing of propranolol treatment was found to block the effects of clenbuterol, a b adrenergic agonist, on locomotor activity. Clenbuterol decreased distance travelled over a 30-min period and this effect was fully blocked by propranolol pretreatment (propranololrclenbuterol : F 1,33 = 4.24, p=0.04). [Mean distance travelled (cm¡S.E.M.) for Veh/Veh, Veh/clenbuterol, propranolol/Veh, and propranolol/clenbuterol groups : 4613.9¡172.0, (Fig. 3 a, right) . Post-hoc analysis on each block indicated that compared to vehicle, 30 mg/kg increased startle magnitude during all blocks and 10 mg/kg increased startle during blocks 2, 3 and 4 (p<0.05). Atipamezole did not affect %PPI (Table 2) .
Expt 3b : a 1 agonist (cirazoline) effects on startle (0-1.0 mg/kg)
The a 1 agonist cirazoline decreased startle magnitude regardless of pulse intensity (cirazoline : F 3,37 =10.01, p=0.0001 ; Table 2 ). Post-hoc analysis conducted on the average startle response (collapsed across intensity) indicated that each dose of cirazoline decreased startle (p<0.01, vs. vehicle). Cirazoline-induced decreases in startle were most prominent in the initial blocks (cirazolinerblock : F 9,111 =2.69, p=0.007) (Fig. 3 b) . Compared to vehicle, 1.0 and 0.5 mg/kg decreased startle during blocks 1 and 2, respectively (p<0.05) (Fig. 3 b, right) . Cirazoline did not affect %PPI (Table  2) . No effects on startle or PPI were found with lower cirazoline doses (0.025, 0.083, 0.25 mg/kg) (Fig. 3 c, Table 2 ). Veh/Veh (p<0.05). The effects of atipamezole appeared to be mildly attenuated by antalarmin as the antalarmin/atipamezole group was not significantly different from Veh/Veh ; however, it was also not significantly different from Veh/atipamezole. To compare with previous experiments, we also conducted an analysis on block 1 (Fig. 4) , finding a significant antalarminratipamezole interaction (F 1,38 =7.45, p= 0.01) with post-hoc tests indicating a significant startle magnitude increase in the Vehicle/atipamezole group compared to Veh/Veh (p<0.05, Tukey's test). A less conservative planned simple comparison revealed a significant reduction of atipamezole effects by antalarmin pretreatment (t test between Veh/atipamezole and antalarmin/atipamezole : p=0.05). Although the effects of atipamezole on %PPI depended on prepulse intensity (atipamezolerintensity : F 2,76 =3.72, p=0.03), subsequent ANOVAs conducted at each intensity separately revealed no significant main effect of atipamezole (Table 3) . Antalarmin also did not affect PPI, and it did not interact with atipamezole (Table 3) .
Discussion
We investigated the mechanisms by which CRF and NE signalling interact to modulate defensive startle behaviours. Acute oCRF administration robustly increased startle reactivity and reduced PPI. The a 2 agonist (clonidine) and the a 1 antagonist (prazosin), but not the b 1/2 adrenergic antagonist (propranolol), significantly reduced the effects of CRF on startle, suggesting that a 2 and a 1 receptors mediate CRF-induced increases in startle reactivity. None of these treatments affected CRF-induced disruptions in PPI. We also found a reciprocal contribution of the CRF 1 receptor to NE signalling effects on startle, with a 2 antagonist (atipamezole)-induced increases in startle attenuated by CRF 1 antagonist (antalarmin) pretreatment. These findings support the hypothesis that NE transmission is required for CRF effects on startle reactivity. These data lend support to a model of dual permissive roles for NE and CRF 1 receptor activation for stress-induced increases in startle. These findings also suggest that the neurotransmission mechanism mediating CRF effects on startle reactivity is dissociable from CRF-mediated changes in PPI. oCRF robustly increased startle in all experiments, consistent with earlier rodent findings wherein r/h-CRF increased startle magnitude (Liang et al. 1992 ; Risbrough et al. 2003 Risbrough et al. , 2004 Swerdlow et al. 1986 Swerdlow et al. , 1989 . In rats, CRF effects on startle have been localized to a hippocampal-septal-BNST circuit expressing CRF 1 and CRF 2 receptors Van Pett et al. 2000) . In mice, both receptors contribute to CRF effects on startle and PPI (Risbrough et al. 2003 (Risbrough et al. , 2004 . Early evidence suggested that NE signalling may be induced by activation of the CRF system. Lee et al. (1994) reported that CRF facilitates NE release in the hippocampal dentate gyrus. Additionally, CRF 1 pharmacological blockade and CRF gene deletion block stress-induced increases in NE release (Griebel et al. 2002 ; Jeong et al. 2000) . Here we identified NE signalling via a 1 receptors as a mechanism required for CRF effects on startle behaviour, since clonidine and prazosin prevented CRF-induced increases in startle. Both drugs were effective at the 120-dB stimuli, while prazosin also reversed CRFinduced increases in startle at 80 dB (Table 1) . These results hint that a 1 and a 2 receptors could mediate startle at different points in the startle circuit and/or alter neuronal excitability in different ways (reduced threshold vs. increased firing rate), although further testing is required to test this speculation. Neither clonidine nor prazosin treatment alone significantly affected startle in the absence of CRF (Table 1) . Thus, it is unlikely that the blockade of CRF-induced increases in startle following clonidine and prazosin pretreatment reflected a summation of opposing effects.
The b 1/2 adrenergic antagonist propranolol had no effect on CRF-induced increases in startle, despite the fact that this pretreatment was clearly behaviourally active in blocking the effects of clenbuterol. Thus, the null effect of propranolol on CRF modulation of startle was not due to incorrect dosing or timing of propranolol treatment. However, it should be noted that the CRF-induced increase in startle in the propranolol experiment, although robust and highly significant, was smaller compared to its effect in the clonidine and prazosin experiments. The possibility that this smaller behavioural window obscured detection of a propranolol effect on CRF-induced increases in startle cannot be excluded. Nonetheless, our propranolol data corroborate previous startle findings that blockade of CRF 1 , but not b 1/2 receptors, reduces stress-induced increases in startle reactivity (Adamec et al. 2007 (Adamec et al. , 2009 . Taken together, the present data suggest that a 2 and a 1 adrenergic receptors modulate the CRF startle effect, while the b 1/2 receptors may not.
After determining that NE signalling, probably via a 1 receptors, is required for the effects of CRF on startle reactivity, we next examined the efficacy of a 2 antagonist (atipamezole) and a 1 agonist (cirazoline) treatments to increase startle reactivity. These studies were based on the hypothesis that if NE release (via blockade of a 2 autoreceptor) or a 1 activation mediate CRF effects on startle, then modulation of these receptors may be sufficient to mimic CRF-induced alterations in startle reactivity. We found that atipamezole (which releases NE), but not cirazoline (which selectively activated a 1 ), increased startle. The inability of cirazoline to increase startle corroborates a recent report that a 1 agonist treatments (cirazoline, methoxamine, or phenylephrine) do not affect baseline startle magnitude in rats, despite activity in other measures (PPI) (Alsene et al. 2006) . Thus, NE release is sufficient to mimic CRF-induced increases in startle, but direct a 1 activation is not.
These findings raise the question of how could increased NE release potentiate startle if direct stimulation of a 1 receptors has no effect? In humans yohimbine, an a 2 antagonist, induces increased CRF release (as measured by increased CRF in cerebrospinal fluid ; Vythilingam et al. 2000) . If the NE-induced release of CRF in turn activates the CRF 1 receptor, then this would explain why atipamezoleinduced increases in startle were attenuated by the CRF 1 antagonist antalarmin (expt 3). Thus, atipamezole may induce CRF release in the BNST either via its induction of NE release and subsequent activation of excitatory NE receptors (a 1 and/or b) at CRFcontaining neurons, or via direct antagonist activity of inhibitory a 2 receptors at CRF-containing neurons (Lorton & Davis, 1987 ; Phelix et al. 1994 ; Shields et al. 2009 ). Our data suggest that atipamezole-induced increases in startle is likely to be via direct blockade of inhibitory a 2 or indirect activation of excitatory b 1/2 receptors at CRF-containing neurons, as activation of a 1 with cirazoline did not increase startle reactivity. These data are also consistent with previous reports suggesting that activation of CRF receptors mediates noradrenergic-related increases in anxiety behaviours. For example, a 2 antagonists (idazoxan) and a 1 agonists (phenylephrine) result in stress-like decreases in exploratory behaviour and a non-selective CRF antagonist (a-helical CRF) blocks phenylephrine-induced decreases in exploratory behaviour (Berridge & Dunn, 1989) . Taken together, the present findings that a 2 agonist and a 1 antagonist treatment disrupt CRFinduced increases in startle and that CRF 1 antagonist treatment attenuates a 2 antagonist-induced increases in startle lend support to a model of dual permissive roles for CRF and NE receptor activation for stressinduced increases in startle.
To integrate these findings, we have proposed a potential circuit model of the CRF/NE signalling effects on startle reactivity (Fig. 5) . Previous reports indicate that the BNST is the site of action for CRF 1 effects on startle (Walker et al. 2009 ). However, unlike our findings following systemic prazosin pretreatment (expt 2b), we observed no effect of a 1 antagonist (4, 12, 40 mg terazosin) infusions in the BNST on CRFinduced startle increases (Gresack et al. unpublished observations) suggesting that a 1 effects on CRF modulation of startle are located elsewhere. It is possible that these effects are via activation of a 1 at the pontine reticular formation (Stevens et al. 1994) which mediates the acoustic startle reflex via activation of motor neurons in the spinal cord (Koch, 1999) . Intrathecal injections of a 1 agonists in rats robustly increases startle reactivity, suggesting that brainstem activation of a 1 receptors may be sufficient to increase startle (Astrachan et al. 1983) . a 1 receptors in the reticular formation are predominantly excitatory by facilitating initial neuronal responsiveness and increasing repetitive firing (Stevens et al. 1994) . Hence, CRF receptor activation may modulate startle by activating two separate pathways that converge at the nucleus reticularis pontis caudalis (PRC) of the startle circuit (Lee et al. 1996) : the BNST-PRC (via glutamate release at the PRC that is independent of a 1 activation) (Dong & Swanson, 2004 ; Holstege et al. 1985) , and the LC-PRC (via NE release and subsequent a 1 receptor activation at the PRC ; Jones & Yang, 1985 ; Strazielle et al. 1999) (Fig. 5) . Because NE release in turn increases levels of CRF (Vythilingam et al. 2000) , inducing NE release via an a 2 antagonist would activate both of these pathways, while direct stimulation of a 1 receptors would not (Fig. 5) . If both pathways are required to achieve a maximal startle response, this model could explain why we did not observe effects of systemic a 1 treatment on startle alone. Further sitespecific injections of NE and CRF signalling blockers at the PRC are required to test this hypothesis.
In the present study, CRF-evoked disruptions in sensorimotor gating were insensitive to manipulation of the noradrenergic system, since clonidine, prazosin, and propranolol did not affect CRF-induced decreases in PPI. Thus, a dichotomy exists between CRF signalling mechanisms for startle and PPI. Downstream signalling mediators of CRF effects on PPI remain unclear. Neither D 1 nor D 2 signalling is required for CRFinduced disruption in mice (Vinkers et al. 2007 , but see Dirks et al. 2003) . Similarly serotonin signalling does not appear to be required for CRF-induced decreases in PPI in rats (Sutherland et al. 2008) . CRF does modulate excitatory glutamatergic synapse transmission at forebrain regions that modulate PPI (Liu et al. 2004 ; Swerdlow et al. 2001) , and thus may be a system for future investigation of mechanisms underlying CRF-induced alterations in PPI.
Finally, none of the pharmacological manipulations of the noradrenergic system affected PPI. These findings diverge from previous reports in rats indicating that a 1 activation (via cirazoline) decreases PPI (Alsene et al. 2006 ; Carasso et al. 1998 ; Swerdlow et al. 2006) , and this effect is blocked by a 2 activation (via clonidine ; Swerdlow et al. 2006) . There are few studies of NE effects on PPI in mice. Indeed, to our knowledge, the present study is the first to describe cirazoline effects in mice, which appear to be different than found in rats, perhaps due to species differences in NE receptor function or distribution (Lorton & Davis, 1987 ; Schultz & Daly, 1973) . In mice, a 2c vs. a 2a receptor subtypes appear to exhibit opposing roles on PPI with a 2c and a 2a null mutation mice exhibiting decreased and increased PPI, respectively (Sallinen et al. 1998 ; Lahdesmaki et al. 2004) . Non-selective activation/blockade of a 2 subtypes by clonidine/ atipamezole could thus result in overall null effect on PPI in the present study. The finding that NE release (a 2 ) and a 1 receptor activation is required for CRF effects on startle hyperreactivity and that CRF 1 activation is required for NE-induced increases in startle may have clinical implications for PTSD. The CRF and noradrenergic systems, both of which influence arousal, have been implicated in the pathophysiology of PTSD (Baker et al. 1999 ; Bremner et al. 1997 ; Geracioti et al. 2008 ). Blockade of a 2 receptors selectively increases acoustic startle in combat veterans with PTSD but not combat controls (Morgan et al. 1995) . These clinical findings, in conjunction with the present preclinical findings, suggest that PTSD subjects may have increased vulnerability to NE effects on startle, perhaps due to increased CRF signalling (and vice versa). Prazosin has shown some promise in treating sleep disturbances in PTSD ) and a 2 agonists may be another novel way to treat PTSD symptoms (Krystal & Neumeister, 2009) . A current clinical trial is also examining the effects of CRF 1 antagonists on PTSD symptomology (clinicaltrials. gov). Our findings support the notion that targeting NE and CRF signalling mechanisms may prove beneficial in specifically treating heightened arousal symptoms associated with PTSD.
